Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BMRN

Biomarin Pharmaceutical Inc

Dec 26 • 04:00PM ET

67.02

Dollar change +0.39
Percentage change 0.59	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: IJH VTI VO VXF VUG XBI MDY VOT IBB IJJ

Scroll to Statements

Index	-	P/E	40.35	EPS (ttm)	1.66	Insider Own	1.24%	Shs Outstand	190.55M	Perf Week	3.60%
Market Cap	12.77B	Forward P/E	20.78	EPS next Y	3.23	Insider Trans	-0.25%	Shs Float	188.22M	Perf Month	2.97%
Income	322.29M	PEG	2.02	EPS next Q	0.55	Inst Own	96.64%	Short Float	2.77%	Perf Quarter	-4.58%
Sales	2.75B	P/S	4.65	EPS this Y	159.19%	Inst Trans	-2.12%	Short Ratio	3.57	Perf Half Y	-19.74%
Book/sh	28.41	P/B	2.36	EPS next Y	43.05%	ROA	4.74%	Short Interest	5.21M	Perf Year	-30.52%
Cash/sh	4.88	P/C	13.73	EPS next 5Y	20.00%	ROE	6.25%	52W Range	61.15 - 99.25	Perf YTD	-30.49%
Dividend Est.	-	P/FCF	39.93	EPS past 5Y	-	ROI	5.36%	52W High	-32.47%	Beta	0.29
Dividend TTM	-	Quick Ratio	2.62	Sales past 5Y	10.23%	Gross Margin	77.12%	52W Low	9.60%	ATR (14)	1.70
Dividend Ex-Date	-	Current Ratio	4.27	EPS Y/Y TTM	116.68%	Oper. Margin	14.23%	RSI (14)	54.69	Volatility	2.61% 2.61%
Employees	3401	Debt/Eq	0.11	Sales Y/Y TTM	19.99%	Profit Margin	11.73%	Recom	1.62	Target Price	96.24
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	159.19%	Payout	0.00%	Rel Volume	0.63	Prev Close	66.63
Sales Surprise	6.01%	EPS Surprise	3.58%	Sales Q/Q	26.69%	Earnings	Oct 29 AMC	Avg Volume	1.46M	Price	67.02
SMA20	1.66%	SMA50	0.84%	SMA200	-14.68%	Trades		Volume	926,162	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$110

Show Previous Ratings

Today 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Dec-24-24 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Dec-19-24 08:38AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? (Zacks)
Dec-11-24 09:50AM	BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Dec-09-24 03:31PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
11:31AM	Loading…
Nov-28-24 11:31AM	Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? (Zacks)
Nov-27-24 09:20AM	Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Healthcare Stocks in 2024? (Insider Monkey)
Nov-21-24 05:26PM	Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Nov-20-24 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Nov-19-24 06:54PM	BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-16-24 10:45AM	BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 (PR Newswire)
Nov-12-24 08:30AM	Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options (Zacks)
Nov-07-24 09:35AM	Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) (Insider Monkey)
Nov-06-24 08:00AM	BioMarin to Participate in Three Upcoming Investor Conferences (PR Newswire)
09:40AM	Loading…
Nov-05-24 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Nov-04-24 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
12:00PM	BioMarin (BMRN) Upgraded to Buy: Here's Why (Zacks)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-01-24 01:12AM	Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) (GuruFocus.com)
Oct-31-24 07:33AM	BioMarin price target raised to $106 from $104 at UBS (TipRanks)
Oct-30-24 12:14PM	Q3 2024 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
10:19AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
03:13AM	Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Oct-29-24 06:30PM	BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:20PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:20PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook (PR Newswire)
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire)
06:32AM	BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth (Insider Monkey)
10:01AM	Loading…
Oct-22-24 10:01AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-17-24 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Oct-16-24 08:30AM	BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET (PR Newswire)
Oct-04-24 10:04AM	Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't? (Zacks)
Oct-01-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) (Zacks)
09:35AM	Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN) (Zacks)
Sep-30-24 07:03PM	Andreas Halvorsen's Strategic Acquisition in BioMarin Pharmaceutical Inc (GuruFocus.com)
07:03PM	Andreas Halvorsen's Firm Expands Grip in BioMarin Pharmaceutical Inc Holding (GuruFocus.com)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Sep-25-24 03:50PM	BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish (Benzinga)
Sep-21-24 09:55AM	BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem (Insider Monkey)
Sep-18-24 08:00AM	BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting (PR Newswire)
Sep-17-24 11:15AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
07:18AM	Ascendis trial data piles pressure on BioMarin (BioPharma Dive)
Sep-16-24 06:45PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research) -17.71%
04:01PM	Ascendis Rockets And Hammers BioMarin On New Results For Growth Drug (Investor's Business Daily)
03:12PM	Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term (Benzinga)
Sep-13-24 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-08-24 02:03AM	BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy? (Insider Monkey)
Sep-04-24 01:30PM	BioMarin, having retrenched, outlines plans for growth (BioPharma Dive)
01:00PM	BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance (PR Newswire)
11:30AM	Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report? (Zacks)
07:30AM	BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time (PR Newswire)
Aug-29-24 11:53AM	BioMarin lays off 225 employees in restructuring efforts (Pharmaceutical Technology)
09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
08:15AM	BioMarin to lay off over 200 employees (BioPharma Dive)
08:00AM	BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY (PR Newswire)
04:12AM	The most expensive drugs in the US (Pharmaceutical Technology)
Aug-28-24 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Aug-23-24 07:56AM	Is the Options Market Predicting a Spike in BioMarin (BMRN) Stock? (Zacks)
Aug-21-24 08:30AM	BioMarin Announces New R&D and Business Development Leadership (PR Newswire)
07:00AM	BioMarin taps Amgen, Roche vets in executive reshuffle (BioPharma Dive)
Aug-19-24 09:00AM	BioMarin to Host 2024 Investor Day on September 4th in New York (PR Newswire)
Aug-13-24 10:34AM	Here's Why You Should Invest in BioMarin (BMRN) Stock Now (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-12-24 12:45PM	BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Aug-09-24 09:15AM	BioMarin Pharmaceutical Inc (BMRN): Are Hedge Funds Bullish on This Elliott Management-Approved Stock Now? (Insider Monkey)
Aug-06-24 02:42PM	When Product Launches Struggle, Biotech Investors Reward Cost Cuts (The Wall Street Journal) +7.95%
01:35PM	Q2 2024 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
11:51AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
10:35AM	BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View (Zacks)
07:45AM	BioMarin pares Roctavian spending as it narrows sales focus (BioPharma Dive)
Aug-05-24 06:00PM	BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:15PM	BioMarin: Q2 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance (PR Newswire)
04:01PM	BioMarin Announces Updated Strategy for ROCTAVIAN to Focus on U.S., Germany and Italy (PR Newswire)
Jul-31-24 09:15AM	Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings (Zacks)
Jul-25-24 06:33AM	FDA agrees wider use of BioMarins BRINEURA for CLN2 (Pharmaceutical Technology)
Jul-24-24 04:05PM	U.S. Food and Drug Administration Approves BioMarin's BRINEURA (cerliponase alfa) for Children Under 3 Years with CLN2 Disease (PR Newswire)
12:10PM	Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again (Zacks)
Jul-23-24 08:00AM	BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET (PR Newswire)
Jul-22-24 10:01AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jul-15-24 08:41AM	Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock? (Zacks)
Jul-01-24 09:20AM	Here's Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Jun-20-24 03:18AM	Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback? (Insider Monkey)
Jun-17-24 08:30AM	BioMarin to Present Data Highlighting Significant Impact of VOXZOGO (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health (PR Newswire)
Jun-11-24 10:57AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Jun-07-24 06:09PM	KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
09:00AM	BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress (PR Newswire)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 08:00AM	BridgeBio data show sustained benefit for achondroplasia drug (BioPharma Dive)
May-25-24 11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-24-24 11:31AM	BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-18-24 05:06AM	4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market (Motley Fool)
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-13-24 04:14PM	Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing (MT Newswires)
May-09-24 06:15AM	The 3 Best Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 08:00AM	BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV (PR Newswire)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer Charles Greg	EVP, Chief Technical Officer	Nov 12 '24	Sale	66.37	5,278	350,324	68,909	Nov 14 02:44 PM
Guyer Charles Greg	Officer	Nov 12 '24	Proposed Sale	66.37	5,278	350,324		Nov 12 02:27 PM
Burkhart Erin	GVP, Chief Accounting Officer	Aug 13 '24	Sale	90.00	714	64,260	14,449	Aug 15 03:57 PM
Burkhart Erin	Officer	Aug 13 '24	Proposed Sale	90.00	714	64,260		Aug 13 11:48 AM
HERON ELAINE J	Director	Jun 03 '24	Option Exercise	63.10	5,047	318,466	101,888	Jun 04 07:29 PM
MEIER RICHARD A	Director	Jun 03 '24	Option Exercise	63.10	6,600	416,460	126,227	Jun 04 07:28 PM
Mueller Brian	EVP, Chief Financial Officer	May 30 '24	Option Exercise	63.10	5,000	315,500	77,159	May 31 06:28 PM
Mueller Brian	EVP, Chief Financial Officer	May 30 '24	Sale	75.19	5,000	375,950	72,159	May 31 06:28 PM
Davis George Eric	EVP, Chief Legal Officer	May 28 '24	Option Exercise	63.10	40,850	2,577,635	97,007	May 30 06:18 PM
Davis George Eric	EVP, Chief Legal Officer	May 28 '24	Sale	74.51	40,850	3,043,802	56,157	May 30 06:18 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Sale	81.62	20,000	1,632,400	474,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Sale	81.14	20,000	1,622,800	474,994	May 13 03:57 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Option Exercise	63.10	1,850	116,735	58,007	May 06 04:45 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Sale	85.01	1,850	157,268	56,157	May 06 04:45 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	May 02 '24	Sale	82.91	5,000	414,550	66,767	May 06 04:40 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Sale	91.26	20,000	1,825,200	474,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Sale	90.99	20,000	1,819,800	474,994	Apr 15 04:21 PM
Burkhart Erin	GVP, Chief Accounting Officer	Apr 10 '24	Sale	90.00	2,286	205,740	16,156	Apr 12 03:07 PM
Davis George Eric	EVP, Chief Legal Officer	Mar 28 '24	Sale	88.34	24,602	2,173,341	55,856	Apr 01 04:54 PM
Slamon Dennis	Director	Mar 18 '24	Option Exercise	79.70	10,000	797,000	40,809	Mar 20 05:13 PM
FUCHS HENRY J	President, Worldwide R&D	Mar 05 '24	Sale	85.18	35,341	3,010,396	212,117	Mar 07 06:54 PM
BIENAIME JEAN JACQUES	Director	Mar 06 '24	Sale	86.71	1,000	86,713	560,203	Mar 07 05:35 PM
BIENAIME JEAN JACQUES	Director	Mar 05 '24	Sale	85.51	1,000	85,510	561,203	Mar 07 05:35 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 05 '24	Sale	87.07	4,000	348,280	94,047	Mar 07 05:32 PM
BIENAIME JEAN JACQUES	Director	Feb 27 '24	Sale	90.35	1,000	90,350	562,203	Feb 29 05:05 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Option Exercise	63.10	15,000	946,500	434,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 08 '24	Sale	89.77	15,000	1,346,550	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Feb 09 '24	Sale	88.28	15,000	1,324,200	419,602	Feb 12 05:20 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Option Exercise	63.10	10,000	631,000	435,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 09 '24	Sale	98.19	10,000	981,900	425,162	Jan 11 02:40 PM
BIENAIME JEAN JACQUES	Director	Jan 10 '24	Sale	96.38	10,000	963,800	425,162	Jan 11 02:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience